Table 5 Summary of studies about lncRNA

Yue H et al. (2016)

MDC1-AS, an antisense long noncoding RNA, regulates cell proliferation of glioma

LncRNA MDC1-AS

Expression of lncRNA in glioblastoma tumor samples has a significant decrease compared to normal tissue.

Zhou Q. et al. (2018)

lncRNAs as potential molecular biomarkers for the clinicopathology and prognosis of glioma: a systematic review and meta-analysis

1-UCA1

2-MALAT1

1- Expression was associated with tumor size and tumor grade.

2- Expression could predict poor overall survival (OS) in patients with glioma.

Wang W. et al (2016)

LncRNA profile study reveals four-lncRNA signature associated with the prognosis of patients with anaplastic gliomas

1- AGAP2-AS1

2- LINC01198

3- MIR155HG

4- TPT1-AS1

-The expression of 1, 2, and 3 was increased in high-grade tumors.

-4 was decreased in high-grade tumors.

Zottel A. et al (2020)

Coding of Glioblastoma Progression and Therapy Resistance through Long Noncoding RNAs

1- MALAT1

2- MEG

3- HOTAIR

4- H19

5- CRNDE

1- Downregulated in glioma

2- Downregulation in human glioma cell lines compared with normal astrocytes

3- Overexpressed in GBM and higher level in serum of patients with glioma specially glioblastoma

4- Expression is significantly increased in glioblastoma tissue, attributed to high tumor grade, and is predictor of poor prognosis.

5- Significant independent prognostic factor for OS and expression correlates with larger tumor size and more recurrence

Mahinfar P. et al. (2021)

Long Non-Coding RNAs in Multidrug Resistance of Glioblastoma

lncRNA’s contribution to multidrug resistance (MDR)

Mechanisms related to MDR:

- Targeting MDR transporters

- Modulating apoptosis

- Targeting DNA repair machinery

- Controlling cancer stem cells

- Regulating epithelial mesenchymal transition